MAY 0 6 2006 M



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Loriann Kazmercyk

Type or print name

12 Wan Jain

May 3, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: McPhee et al.

Art Unit: 1654

Application No.: 10/825,693

Examiner: Thomas S. Heard

Docket No. CT-2770-NP

For: MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents

Filed: April 16, 2004

P.O. Box 1450

Alexandria, VA 22313-1450

PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(a)

Sir:

This is a petition to add

Kenneth M. Boy

as an inventor of the above-identified patent application. The correct inventors should be Stanley D'Andrea, Zhizhen Barbara Zheng, David J. Carini, Barry L. Johnson, Jeffrey Allen Campbell, Kenneth M. Boy, Fiona Mcphee, Andrew Charles Good, and Paul Michael Scola.

In support of this petition, the following documents are included herewith:

- 1) Statement of Inventor to be Added and Written Consent of Assignee;
- 2) A newly executed Declaration including all of the inventors;

05/08/2006 HBIZUNES 00000026 193880 10825693



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.nepto.gov



Bib Data Sheet

CONFIRMATION NO. 9049

SERIAL NUMBE 10/825,693	ĒR	FILING OR 371(c) DATE 04/16/2004 RULE	(CLASS 514	GROUP ART UNIT 1654		ATTORNEY DOCKET NO. CT-2770 NP		
Jeffrey Aller Stanley D'A Zhizhen Bar Andrew Cha David J. Ca Barry L. Joh Paul Michae Kenneth M I ** CONTINUING D This appln of ** FOREIGN APPI	n Car ndres rbara arles rini, \ nnsor el Sco Boy, DATA claims LICA	— yes — no — wet an	ed; * \$ 04/16/2 *** GRANTI			EETS WING	TOT,		INDEPENDENT CLAIMS
Verified and Acknowledged Examiner's Signature Initials				СТ	0		56		5
ADDRESS 23914									
TITLE MACROCYCLIC IS	soq	UINOLINE PEPTIDE II	NHIBITO	ORS OF HEPA	TITIS	C VIRUS	8		
RECEIVED N	lo	Authority has been gi to charge/cre for following:	nority has been given in Paper to charge/credit DEPOSIT ACCOUNT for following:			☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other ☐ Credit			



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 P.O. Box 1450

Alexandria, Virginia	22313-1450
www.uspto.gov	

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/825,693	04/16/2004	1654	2020	CT-2770 NP		56	5

CONFIRMATION NO. 9049

CORRECTED FILING RECEIPT

OC00000019481384

23914 LOUIS J. WILLE BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT P O BOX 4000 PRINCETON, NJ 08543-4000

Date Mailed: 07/05/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Fiona McPhee, Wallingford, CT; Jeffrey Allen Campbell, Glen Gardner, NJ; Stanley D'Andrea, Meriden, CT; Zhizhen Barbara Zheng, Cheshire, CT; Andrew Charles Good, Wallingford, CT; David J. Carini, Wallingford, CT; Barry L. Johnson, Wallingford, CT; Paul Michael Scola, Glastonbury, CT; Kenneth M Boy, Residence Not Provided;

Power of Attorney: The patent practitioners associated with Customer Number 23914.

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/463,423 04/16/2003

Foreign Applications

If Required, Foreign Filing License Granted: 09/17/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/825,693

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).